Calliditas Therapeutics' major owners have appointed a nomination committee for the AGM 2024. The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of: Patrick Sobocki, appointed by Stiftelsen Industrifonden, Karl Tobieson, appointed by Linc AB, Spike Loy, appointed by BVF, Elmar Schnee (chairman of the board of directors). The nomination committee shall, before the annual general meeting 2024, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.2 SEK | +0.10% | +81.83% | +63.81% |
31/05 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
31/05 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.81% | 106.08Cr | |
+15.54% | 7.85TCr | |
+13.29% | 900.15Cr | |
+58.17% | 496.1Cr | |
-14.94% | 483.61Cr | |
-.--% | 372.43Cr | |
-26.63% | 218.54Cr | |
+16.75% | 211.67Cr | |
-37.97% | 194.2Cr | |
-0.50% | 164.41Cr |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024